Labcorp has significantly expanded its strategic collaboration with PathAI to roll out PathAI’s AI-powered digital pathology platform across its extensive U.S. laboratory network. The agreement builds on prior work and aims to accelerate adoption of AI-assisted pathology workflows for faster, more consistent diagnostic insights in cancer and other diseases, ultimately improving turnaround times, reducing inter-observer variability, and enhancing patient care through precision diagnostics.
Glimpse:
Under the expanded multi-year agreement, Labcorp will deploy PathAI’s AISight digital pathology platform and AI algorithms in multiple high-volume U.S. labs, starting with key anatomic pathology sites. The platform digitizes glass slides, applies AI models for cell detection, biomarker quantification, and diagnostic support in oncology, with initial focus on breast, prostate, lung, and colorectal cancers. Labcorp gains exclusive use of certain PathAI algorithms for clinical workflows, while both companies collaborate on validation, real-world evidence generation, and future algorithm co-development. The rollout is expected to improve diagnostic accuracy, streamline pathologist review, and support Labcorp’s leadership in comprehensive cancer diagnostics.
Labcorp, one of the world’s largest clinical laboratory services providers, has announced a major expansion of its long-standing partnership with PathAI, a global leader in AI-powered pathology solutions. The new multi-year agreement, revealed on February 27, 2026, will bring PathAI’s AISight digital pathology platform and suite of AI algorithms into routine use across Labcorp’s extensive U.S. anatomic pathology network, marking one of the largest real-world deployments of digital and AI pathology to date.
The expanded collaboration builds on successful earlier work between the two companies, including joint algorithm development and validation studies. Labcorp will now integrate PathAI’s AISight scanner and cloud-based AI platform into select high-throughput labs, beginning with key sites focused on cancer diagnostics. Pathologists will be able to digitize traditional glass slides at scale, use AI to pre-screen and quantify cells (e.g., tumor-infiltrating lymphocytes, PD-L1 expression, HER2 scoring), and receive AI-assisted decision support for complex cases. Initial applications target breast, prostate, lung, and colorectal cancers, with plans to expand to additional indications such as melanoma, bladder cancer, and hematopathology.
The deployment aims to address persistent challenges in pathology: long turnaround times due to manual slide review, inter-observer variability in scoring biomarkers, and increasing caseloads driven by aging populations and rising cancer incidence. By providing AI-generated heatmaps, cell counts, and preliminary classifications, the platform allows pathologists to focus on interpretive judgment rather than repetitive counting or initial screening. Labcorp expects the technology to reduce diagnostic variability, shorten time-to-result for critical biomarkers, and support more consistent application of guideline-based scoring across its network.
Both companies will collaborate on generating real-world evidence to demonstrate the clinical and operational impact of AI-assisted pathology, including studies on diagnostic concordance, time savings, and patient outcomes. PathAI will also work with Labcorp to further refine its algorithms using anonymized data from Labcorp’s vast case volume, ensuring models remain robust across diverse U.S. patient populations. The agreement includes provisions for exclusive use of certain PathAI algorithms within Labcorp’s clinical workflows, while preserving PathAI’s ability to commercialize its platform broadly.
The expansion reflects the accelerating shift toward digital and AI-enabled pathology in the U.S., where laboratories face mounting pressure to deliver faster, more precise results amid pathologist shortages and increasing complexity of cancer diagnostics. Labcorp’s nationwide scale combined with PathAI’s leading AI pathology tools positions the partnership to set new benchmarks for efficiency and quality in anatomic pathology services.
“By bringing PathAI’s advanced digital and AI capabilities deeper into our network, we are taking a major step forward in delivering faster, more consistent, and more accurate pathology insights to physicians and their patients across the country.”
By
HB Team
Related News
